ST. LOUIS–(BUSINESS WIRE)–C2N Diagnostics, a leading provider of advanced brain health diagnostics, announced today that it has partnered with Grupo Fleury (BVMF: FLRY), one of Brazil’s leading healthcare companies, to introduce blood-based testing for the early detection of Alzheimer’s into patient care Brazil. The goal of the partnership is to introduce the most advanced set of plasma biomarkers to detect changes indicative of the presence of Alzheimer’s disease pathology in patients with memory difficulties.
The announcement of the partnership between C2N and Grupo Fleury takes place to coincide with World Alzheimer’s Day, which every September is part of World Alzheimer’s Month which focuses on uniting people from all parts of the world to raise awareness about disease and the importance of early detection and post-diagnosis support based on the latest innovations in care.
Two more C follow2N international initiatives. The company participates with the Davos Alzheimer’s Collaborative in the Global Health Care Preparedness Project, in which Brazil is one of six countries with sites linked to C2N’s PrecivityAD® blood test to improve the timely and accurate diagnosis of Alzheimer’s.
AlsoC2N announced last month a partnership with Healius Ltd (ASX:HLS), one of Australia’s leading publicly traded healthcare companies, aimed at bringing C2N’s PrecivityAD blood test and related brain health biomarkers to the forefront of memory and dementia care in Australia.
Alzheimer’s disease in Brazil
Data from the Brazilian Ministry of Health estimates that there are 1.2 million cases of Alzheimer’s in Brazil, most of them without a confirmed diagnosis. The number of people living with this disease around the world is 35.6 million.
“Grupo Fleury is a leading organization with a long history of providing quality healthcare services to patients across Brazil, including diagnostic and precision medicine. We are honored to work with this team as part of a shared global commitment to improve the standard of care for patients with memory problems,” said Dr. Joel Braunstein, co-founder and CEO of C2N diagnosis.
added dr Ilana Fogelman, a Brazilian physician and also co-founder and scientific advisor to C2N.: “Patients deserve an early and accurate diagnosis, which is the first step towards appropriate treatment and optimal care planning. Under Grupo Fleury’s leadership, we look forward to bringing our Precivity-related blood testing products to patients in Brazil in a convenient and universally accessible way.”
“Our team of pathologists and scientists believe in the quality and innovation of C₂N Diagnostics. Brazil is a large, diverse country, and we are deeply committed to finding new and innovative ways to reach patients with the testing options they want. Alzheimer’s disease knows no borders – it affects people in all parts of the world and across our country. We are proud of this partnership with C2N and look forward to the promises it keeps,” said Dr. Edgar Gil Rizzatti, Executive Director Medical, Technical and Business B2B of Grupo Fleury.
The two companies will soon provide more details on the testing offerings and how doctors in Brazil can access them for the benefit of their patients and their families.
About C2N Diagnostics, LLC
C2N Diagnostics is a leader in advanced brain health diagnostics with a vision to bring Clarity Through Innovation™. C2N strives to provide exceptional laboratory services and products in the field of brain health. C2N’s biomarker services and products are used for: clinical decision making to improve patient care, including diagnosis and treatment monitoring; Maximizing the quality and efficiency of clinical trials testing novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand emerging disease mechanisms, identify novel treatment targets, and conduct critical epidemiological studies to improve public health worldwide. Visit www.C2N.com for more information.
About Fleury Group
Grupo Fleury is a national leader in Brazil in the fields of diagnostics and precision medicine. With the recent acquisition of Grupo Pardini, the company employs over 20,000 people and offers over 245 million examinations, 39 brands and 3,500 tests in 37 different medical specialties. Among the latest innovations on offer is the Fleury Genomics platform, a channel dedicated to providing customers and physicians with excellent service, enabling genetic testing of saliva, blood and biopsy samples to be performed entirely online upon medical request for customers in all Regions of allows the country and the world. It is also a pioneer in the concept of the Integrated Diagnostic Medicine Center, offering a complete diagnostic solution, medical consultation and unique services such as Fleury Kids for childcare; Gestar Fleury, dedicated to fetal medicine; Osteomuscular Image, dedicated to musculoskeletal disorders; between others. In primary care, it works with the SantéCorp brand. In the therapeutic area, it maintains an infusion center. And in human reproduction with Fleury Fertilidade. Fleury has service units in the cities of São Paulo (SP), Santo André (SP), São Bernardo do Campo (SP), São Caetano do Sul (SP), Barueri (SP), Cotia (SP), Campinas (SP) and Jundiaí (SP), in addition to Brasília (DF). Grupo Fleury website: www.fleury.com.br